Test-Negative 4 vs 3 Dose Non-Matched Severe Disease VE

Design	Control	Start Quarter	Adjusted	n		VE	95% CI
1	3	Q4 2021	N	2709	 	0.066	(-0.162,0.293)
2	3	Q4 2021	Υ	2709	├	0.426	(0.214,0.638)
3	1	Q2 2022	N	29323	-	0.076	(-0.173,0.273)
4	2	Q2 2022	N	26944	=	0.108	(-0.132,0.298)
5	1	Q2 2022	Υ	29323		0.367	(0.185,0.509)
6	2	Q2 2022	Υ	26944	<u> </u>	0.395	(0.203, 0.541)
7	1	Q3 2022	N	15221	 	0.159	(-0.117,0.368)
8	2	Q3 2022	N	15480		0.070	(-0.217,0.289)
9	3	Q3 2022	N	1485	<u> </u>	0.373	(0.155,0.590)
10	1	Q3 2022	Υ	15221		0.377	(0.159,0.539)
11	2	Q3 2022	Υ	15480	<u> </u>	0.312	(0.064,0.494)
12	3	Q3 2022	Υ	1485		0.318	(0.048,0.588)
13	1	Q4 2022	N	5556		0.066	(-0.400,0.376)
14	2	Q4 2022	N	6481		-0.352	(-1.116,0.136)
15	3	Q4 2022	N	516		-0.133	(-0.676,0.409)
16	1	Q4 2022	Υ	5556	-	0.212	(-0.217,0.490)
17	2	Q4 2022	Υ	6481	-	0.142	(-0.447,0.491)
18	3	Q4 2022	Υ	516		-0.364	(-1.092,0.365)
					-0.5 -0.25 0 0.25 0.5 0.75		